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1. Introduction
   Preservatives in ophthalmic solutions have long been 
known to cause toxic effects on the cornea. The most 
frequently used preservative in eye drops, and one 
that has among the highest toxicity, is benzalkonium 
chloride (BAC)[1-3]. This quarternary ammonium has 
been shown to have a variety of pathological effects, 
including tear film instability, conjunctival squamous 
metaplasia, breakdown of conjunctival immunological 
tolerance and cytotoxicity of corneal epithelial, stromal, 
and endothelial cells[4-7]. 
   Clinically, use of BAC may cause dry eyes, red 
eyes, itchy eyes, photophobia, and other signs of 
ocular irritation[8]. Consequences of the use of these 
preservatives in the eye have included chronic 
inflammation and hypersensitivity reactions like 
cicatricial pemphigoid and Steven -Johnson’s 
syndrome[2,7,9]. BAC plays an important role in ocular 
surface damage, especially as its effects are dose- and 
time-dependent[4,8]. 
   In our unusual finding, the patient developed stromal 
opacity almost immediately after one instillation of 
topical tropicamide containing benzalkonium chloride, 
and to the best of our knowledge, this is the first 
reported case of such a condition.
2. Case presentation
  A 64-year-old Malay gentleman presented to our 
clinic for painless progressive blurring of vision for the 
past 1 year. He was afflicted with poorly-controlled 
diabetes mellitus and hypertensive heart disease, under 
medical follow-up in our centre. On examination, the 
This patient is a 64-year-old man who presented with painless progressive blurring of vision for 
one year. After a routine fundoscopy preceded by dilatation of both eyes with a drop of topical 
tropicamide, the left eye was noted to have stromal edema temporally. This was attributed to the 
preservative (BAC) in the medication. The stromal oedema persisted over the following weeks 
despite administration of a topical steroid, and was associated with deterioration in visual acuity 
to 6/30 (PH 6/21). This case reminds us that clinicians should be vigilant during instillation of any 
preservative-containing drops, even in routine practices like dilatation. Far from being restricted 
to chronic use of preservative-containing drugs, toxicity with BAC can occur even upon a single 
application. Ideally, all eyedrops should be single-use topical drug formulations, but in the 
absence of this option, it is imperative that ophthalmic drug prescription be done with adequate 
clinical justification.
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vision in his right eye was 6/60 (PH 6/60), while that of 
the left eye was 6/15 (PH 6/12).  He was noted to have 
bilateral cataract, which was more dense on the right 
than the left. The right eye showed posterior subcapsular 
cataract 2+ and nuclear sclerosis 2+, while the left had 
nuclear sclerosis 2+. 
   The remainder of the anterior segment examination 
was unremarkable. Intraocular pressure was within 
normal limits. We proceeded with a routine fundus 
examination, which was preceded by dilatation of both 
eyes with topical tropicamide. On fundoscopy, the optic 
disc in both eyes was pink, with a cup-disc-ratio of 0.3. 
There was no evidence of retinopathy.
Unfortunately, after dilatation, it was noted that the left 
eye had developed stromal edema temporally, extending 
from 2-5 o’clock and radiating towards the central 
visual axis. This was attributed to the preservative 
(benzalkonium chloride) in the topical tropicamide, as 
no other topical eyedrops had been administered during 
examination. Patient was reviewed again 2 weeks later, 
but there was no improvement of the left eye stromal 
oedema. Providentially, there was no impairment of his 
visual acuity, which remained static at 6/15 (PH 6/12). 
He was started on topical predforte 1.2% 6 hourly and 
preservative-free artificial tears 4 hourly. 
  On subsequent weekly follow up, the stromal oedema 
persisted, and sadly, his left eye visual acuity had now 
deteriorated to 6/30 (PH 6/21). Specular microscopy was 
performed; his right eye had an endothelial cell count 
of 2 210 cells/mm2, while that of the left was 2 041 cells/
mm2. On our latest examination at 4 months after his first 
visit, the area of stromal oedema remained the same. 
Currently, he is being maintained only on preservative-
free artificial tears 4 hourly, and is planned for right eye 
phacoemulsification with posterior chamber intraocular 
lens implantation.
Figure 1. Anterior segment photograph showing stromal opacity 
in paracentral area of left cornea.
3. Discussion
  Benzalkonium chloride is the most widely used 
preservative in opthalmological solutions. With a wealth 
of literature testifying to the deleterious effects of this 
substance on the ocular surface, there is yet no denying 
the equally important advantages to be gained by its 
use. Messmer et al stated that preservatives are a legal 
requirement for eye drops in multidose containers[1]. 
Besides their role in stabilization and preservation 
of ophthalmic preparations[1,10], they also enhance 
intraocular penetration of drugs[11,12].  
  On the downside, this effect on corneal permeability 
has been correlated with electrophysiological changes of 
the corneal tissue, which may be indicative of epithelial 
toxicity[12]. Besides that, benzalkonium chloride has also 
been reported to impair induction of immune tolerance 
in a murine model, thus resulting in breakdown of 
immune balance of the conjunctiva[7].
  Across the board, there have been many instances 
of benzalkonium chloride toxicity. When used as a 
preservative in contact lens disinfecting solutions, 
benzalkonium chloride (BAC) has been reported to 
cause anterior chamber inflammation in a patient post 
extracapsular cataract extraction[13]. In another study of 
previously untreated patients with ocular hypertension 
who were given a short-term course of BAC-preserved 
timolol in one eye and preservative-free timolol in the 
other, this induction of anterior chamber inflammation 
was likewise demonstrated in the BAC-treated eyes[14]. 
On a different level, cytotoxicity of BAC on conjunctival 
and corneal epithelial cells has also been demonstrated, 
both in vitro and in vivo[15-17]. 
   Paradoxically, our patient neither had intraocular 
inflammation or epitheliopathy; in his case, the 
BAC-related toxicity took the form of a corneal 
decompensation-like picture, in which he developed 
stromal edema despite the presence of a normal 
endothelial cell count. 
  The circumstances under which this condition occurred 
render this case especially intriguing, as despite his 
medical comorbidities, this unfortunate gentleman had 
no underlying ocular disease apart from the normal age-
related cataract. Ironically, he developed a persistent 
visual impairment secondary to stromal edema in the 
less cataractous eye, which can be directly attributed 
to the effect of the BAC-preserved dilating drops. As 
far as we know, there have been no reports of a similar 
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occurrence of stromal oedema secondary to BAC, and 
the pathophysiology of this phenomenon still remains 
elusive. 
  Our  case provides addi t ional  evidence that 
clinicians should be vigilant during instillation of any 
preservative-containing ophthalmic solution, even in 
apparently routine practices like dilatation.
Learning points: 
  •Far from being restricted to chronic use of 
preservative-containing drugs, toxicity with BAC can 
occur even upon a single application, as demonstrated 
in this patient.
  •Measures to reduce the risk of potential toxicity 
with BAC include using a small drop size or a less toxic 
alternative to BAC, especially in patients who require 
high doses or long duration of topical ophthalmic 
medication. 
  •Ideally, all preservatives should be avoided where 
single-use topical drug formulations are available. 
In the absence of this option, it is imperative that 
ophthalmic drug prescription be done with adequate 
clinical justification.
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